A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms R2
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 1 May 2017 to 15 Feb 2019.
    • 07 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 15 Feb 2018.
    • 04 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top